AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study.

Paula Dominguez-Gomez¹, Alberto Zingaro², Caterina Balzotti², Michael Leitner³, Noelia Jacobo-Piqueras³, Mariano Vazquez⁴, Georg Rast³, Jazmin Aguado-Sierra²

¹ELEM Biotech, Pier 07, Via Laietana, 26, Barcelona, 08003, Spain; University Pompeu Fabra, Carrer de Tànger, 122-140, Barcelona, 08018, Spain. Electronic address: pdominguez@elem.bio.

²ELEM Biotech, Pier 07, Via Laietana, 26, Barcelona, 08003, Spain.

³Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, Biberach an der Riß, 88400, Germany.

⁴ELEM Biotech, Pier 07, Via Laietana, 26, Barcelona, 08003, Spain; Barcelona Supercomputing Center, Plaça d'Eusebi Güell, 1-3, Barcelona, 08034, Spain.

PubMed DOI

Abstract

Drug-induced QT interval prolongation is a key biomarker of proarrhythmic risk and central to drug cardiac safety evaluation alongside in vitro assays and animal studies, yet current preclinical frameworks provide limited insight into how experimental uncertainty and extreme exposures translate into real-world arrhythmic risk despite both factors critically modulating outcomes. To address this, we…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.